Abstract 1610: Local delivery of anti CTLA4 mediates cDC1 dependent eradication of HNSCC with limited IRAEs in a preclinical model of oral squamous cell carcinoma

Head and neck squamous cell carcinoma (HNSCC) ranks 6th in cancer incidence worldwide and has a five-year survival rate of only 63%. Despite advances in curative-intent therapies over the past three decades, rates of recurrence exceed 50% and long-term toxicities remain unacceptably morbid. Immunotherapies - principally immune checkpoint inhibitors (ICI) such as αPD-1 and αCTLA-41 antibodies which restore endogenous antitumor T cell immunity -...